Cell-El, The ASD Bio-Marker Company
Cell-El’s team is working to change the Autism Spectrum Disorder (ASD) screening and treatment paradigms using personalized medicine – Identify children at a younger age who are at increased risk for ASD
MISSION
DIAGNOSTIC STUDY
Cell-El’s research of screening bio-markers could lead to an objective and earlier assessment of the risk of developing ASD. This would pave the way to earlier intervention and better outcomes.
PARTICIPATE
Parents and clinicians are invited to join the Cell-El team in its multinational clinical collaborations. The ongoing study has approvals from the Helsinki ethics committees and the Israeli Ministry of Health.
What happens at the screening test?
The entire procedure takes less than an hour. It involves:
- Signing a consent form
- Completing medical questionnaires
- Drawing venous blood
- May include providing stool and / or urine sample
- The participant does not have to fast
The drawing of blood is done by a standard procedure with minimal risk to the patient.
Click here to read more about our study.
- Sign Up
We look forward to your participation in the Cell-El screening study. Please read the information below regarding the inclusion and exclusion criteria for the following cohorts: 1. Infants and their mothers and 2. Children pre and post Stem Cell Therapy (SCT). Then please fill out the appropriate form. Please note: At this time we are only recruiting participants residing in Israel.
- Cohorts of infants and their mothers: Mothers of high-risk infants and infants aged 10-19 months not diagnosed with ASD, but with a sibling diagnosed with ASD according to Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV (299.00) or DSM-V (299.00) or
- Cohorts of children pre and post SCT: Male and female children age 2-18 years old diagnosed with autism spectrum disorder (ASD) according to Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV (299.00) or DSM-V (299.00) undergoing stem cell therapy.
- For all cohorts: Informed consent signed by the parents
For all cohorts:
- Child and/or mother completed treatment with systemic steroids or immune suppressants less than 4 weeks before the screening visit
- Child and/or mother diagnosed with severe infectious diseases or sepsis over the last 6 months
- Child and/or mother with hematological or malignant disorder
- Child with ASD treated for a severe convulsive disorder
For children in the SCT cohort:
- No new planned immune-modulating treatment (other than SCT) for at least 6 months before or after planned stem cell transplantation date.
If you are a parent or a clinician of a child diagnosed with ASD, please click here to fill out the appropriate form.
- More Information
Read our research and peer reviewed articles. For any additional questions, please fill out the form below
- Published February 2023: Autism Spectrum Disorder Diagnosis using a New Panel of Immune – and Inflammatory – Related Serum Biomarkers: A Case-Control Multicenter Study, Frontiers in Pediatrics
- Autism Spectrum Disorders (ASD) – Searching For the Biological Basis For behavioral Symptoms And new Therapeutic Targets, Frontiers in Neuroscience and Frontiers in Pediatrics
- Immunological and autoimmune considerations of Autism Spectrum Disorders, Journal of Autoimmunity
To receive more information, please fill out the form below.